
Jan 9 (Reuters) - The U.S. Environmental Protection Agency will reassess the safety of herbicide paraquat, its administrator Lee Zeldin said on Friday on X, adding that the body is requiring manufacturers to thoroughly prove that current uses are safe in real-world conditions.
Syngenta, which markets paraquat under the brand name Gramoxone, is among the herbicide's major sellers.
The Swiss-based agricultural chemical company is facing several lawsuits in the U.S., where plaintiffs allege exposure to paraquat caused them to develop Parkinson's, a degenerative brain disease that leads to loss of muscle coordination.
It has previously said there was "no credible evidence" that paraquat causes Parkinson's.
In agricultural settings, paraquat is mostly applied to soybean, corn and cotton crop fields to control invasive weeds and grasses, according to the Environmental Protection Agency.
(Reporting by Costas Pitas and Pooja Menon; Editing by Alan Barona)
LATEST POSTS
- 1
Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide - 2
Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.' - 3
Ancient fire discovery marks significant milestone in human history - 4
Japan deploys the military to counter a surge in bear attacks - 5
The 12 biggest space stories of 2025 — according to you
Finding Your Motivation: Moves toward a Satisfying Life
More Than 110 New Species Discovered In Deep Waters Off Australia
Artemis II updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
Astonishing Deserts All over The Planet You Really want To Visit
Triumph's 400 Range Has Just Changed In India, And Here's Why
How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker












